



15 March 2024

Sydney, Australia

Cleansing Statement

Nyrada Inc (ASX: NYR), a drug discovery and development company specialising in novel small molecule therapeutics to treat neurological and cardiovascular diseases today issued further to the Appendix 2A lodged on 15 March 2024:

- 23,400,000 CHESS Depositary Interests (CDIs) of Capital Raising Program as announced on 6 March 2024.

NYR gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:

- 1 The CDIs were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
- 2 As at the date of this notice, NYR has complied with:
 - (a) The provisions of Chapter 2M of the Corporations Act as they apply to NYR; and
 - (b) Section 674 of the Corporations Act.
- 3 As at the date of this notice, there is no information that is “excluded information” of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under section 708A(6)(e) of the Corporations Act.

For and on behalf of the Board,

Yours faithfully,

A handwritten signature in black ink, appearing to read 'D. Franks'.

David Franks
Company Secretary

-ENDS-



About Nyrada Inc

Nyrada is a drug discovery and development company specialising in novel small-molecule drugs to treat neurological and cardiovascular diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a drug to treat brain injury, specifically traumatic brain injury and stroke, and a cholesterol lowering drug. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

www.nyrada.com

Authorised by Mr. John Moore, Non-Executive Chair on behalf of the Board.

Investor & Corporate Enquiries:

Dimitri Burshtein

T: 02 9498 3390

E: info@nyrada.com

Company Secretary:

David Franks

T: 02 8072 1400

E: David.Franks@automicgroup.com.au

Media Enquiries:

Catherine Strong

Citadel-MAGNUS

T: 02 8234 0111

E: cstrong@citadelmagnus.com

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.